Harry H Yoon - Mayo Clinic - Rochester

基本信息

浏览量：92

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 115 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

395MO Tislelizumab (TIS) + Chemotherapy (CT) Vs Placebo (PBO) + CT in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): PD-L1 Biomarker Analysis from RATIONALE-306

E. Raymond, J. Xu, K. Kato,R. Hubner,Y. Shu,S.R. Park,T. Kojima,L.S. Wyrwicz,D. Tougeron,K. Geboes,E. Van Cutsem,R.A. Pazo Cid,A. Zaanan,S-A. McLachlan, H. Wu,J. Shi, L. Li, S. Yan,H. Yoon

Annals of Oncology (2024): S159

引用0浏览0引用

Advances in Immunotherapy in Esophagogastric Cancer

Khalid Jazieh,Harry Yoon,Mojun Zhu

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICAno. 3 (2024): 599-616

引用0浏览0WOS引用

Rivoceranib, a VEGFR-2 Inhibitor, Monotherapy in Previously Treated Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (ANGEL Study): an International, Randomized, Placebo-Controlled, Phase 3 Trial

Yoon-Koo Kang,Min-Hee Ryu,Maria Di Bartolomeo,Ian Chau,Harry Yoon,Jong Gwang Kim,Keun-Wook Lee, Sang Chul Oh,Atsuo Takashima,Anna Kryzhanivska,Yee Chao,Ludovic Evesque,Michael Schenker,Arlo McGinn,Yufan Zhao, Jennifer Lee,Lucjan Wyrwicz,Narikazu Boku

Gastric Cancer（2024）

引用0浏览0WOS引用

Tislelizumab (TIS) Plus Chemotherapy (CT) Vs Placebo (PBO) Plus CT in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): PD-L1 Biomarker Analysis from RATIONALE-306

E. Raymond,J. Xu,K. Kato,R. Hubner,Y. Shu,S. R. Park, T. Kojima,L. S. Wyrwicz,D. Tougeron,K. Geboes,E. Van Cutsem,R. A. Pazo Cid,A. Zaanan,S-A. McLachlan, H. Wu,J. Shi, L. Li, S. Yan,H. Yoon

ANNALS OF ONCOLOGY (2024): S159-S159

引用0浏览0引用

CLDN18.2 Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma: Results of ELIMYN18.2 Phase 1b Clinical Trial

Gregory P. Botta,Ronan Joseph Kelly, Zhaohui Jin, Hong Ma,Geoffrey Yuyat Ku, Dan Zhao, Rutika Mehta,Julia C. Carnevale, Gloria Sierra,Jie Jia,Raffaele Baffa, Zhonghai Li, Dae Won Kim,Harry H. Yoon

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 356-356

引用0浏览0引用

AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab (OCI) + Tislelizumab (TIS) with Chemotherapy (chemo) in Patients (pts) with Stage IV Gastric/gastroesophageal Adenocarcinoma (GC/GEJC)

Se Hyun Kim,Gyeong-Won Lee,Byoung Yong Shim, David R. Spigel,Her-Shyong Shiah,Sophia Frentzas,Harry H. Yoon,Feng Wang,Meili Sun,Timothy Dudley Clay,Hao Zheng,Wei Tan, Ziqi Zhou,Ruihua Wang,Yi Ba

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

Life-threatening "Hyper-Progression" on Immunotherapy Revealed As Pseudo-Progression in DNA Mismatch Repair Deficiency: a Case Report

Mojun Zhu, Chitra Ganesan,Siobhan Flanagan,Harry H. Yoon

JOURNAL OF GASTROINTESTINAL ONCOLOGYno. 1 (2023): 435-441

引用0浏览0WOS引用

Table S1 from Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis

Harry H. Yoon,Qian Shi,Erica N. Heying,Andrea Muranyi,Joerg Bredno,Faith Ough,Azita Djalilvand,June Clements,Rebecca Bowermaster,Wen-Wei Liu,Michael Barnes,Steven R. Alberts,Kandavel Shanmugam,Frank A. Sinicrope

openalex（2023）

引用0浏览0引用

Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy As First-Line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (RATIONALE-306): a Global, Randomised, Placebo-Controlled, Phase 3 Study

Harry H. Yoon,Ken Kato,Eric Raymond,Richard Hubner,Yongqian Shu,Yueyin Pan,Yi Jiang,Jingdong Zhang,Sook Ryun Park, Takashi Kojima,Chen-Yuan Lin,Lucjan S. Wyrwicz, David Tougeron,Ryu Ishihara, Liyun Li, Hongqian Wu, Yanyan Peng, Shican Yan,Jianming Xu

The Lancet Oncology（2023）

引用23浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn